AKTX Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of 46.57%. Akari Therapeutics PLC's return on equity of -- beat Cellectis SA's return on equity of -31.46%.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7172.73%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 305.59%. Given that Akari Therapeutics PLC has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics PLC is more attractive than Cellectis SA.

Akari Therapeutics PLC has a beta of 0.575, which suggesting that the stock is 42.51% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.219, suggesting its more volatile than the S&P 500 by 221.86%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $12.7M. Akari Therapeutics PLC's net income of -$2.9M is lower than Cellectis SA's net income of $5.9M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 3.39x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7172.73%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 185.08%. Given that Akari Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics PLC is more attractive than DBV Technologies SA.

Akari Therapeutics PLC has a beta of 0.575, which suggesting that the stock is 42.51% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics PLC's net income of -$2.9M is higher than DBV Technologies SA's net income of -$23M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of -9.55%. Akari Therapeutics PLC's return on equity of -- beat Edap TMS SA's return on equity of -39.5%.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7172.73%. On the other hand Edap TMS SA has an analysts' consensus of $8.50 which suggests that it could grow by 548.86%. Given that Akari Therapeutics PLC has higher upside potential than Edap TMS SA, analysts believe Akari Therapeutics PLC is more attractive than Edap TMS SA.

Akari Therapeutics PLC has a beta of 0.575, which suggesting that the stock is 42.51% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.124, suggesting its less volatile than the S&P 500 by 87.615%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $21.7M. Akari Therapeutics PLC's net income of -$2.9M is lower than Edap TMS SA's net income of -$2.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 0.71x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of -31.41%. Akari Therapeutics PLC's return on equity of -- beat Trinity Biotech PLC's return on equity of --.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7172.73%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 2677.78%. Given that Akari Therapeutics PLC has higher upside potential than Trinity Biotech PLC, analysts believe Akari Therapeutics PLC is more attractive than Trinity Biotech PLC.

Akari Therapeutics PLC has a beta of 0.575, which suggesting that the stock is 42.51% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 1.210, suggesting its more volatile than the S&P 500 by 20.986%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Trinity Biotech PLC quarterly revenues of $15.2M. Akari Therapeutics PLC's net income of -$2.9M is higher than Trinity Biotech PLC's net income of -$4.8M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 0.10x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.